RxDoctor Payments Data

Michael Calderone, DPM

Foot & Ankle Surgery · Millville, NJNPI 1376907071

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (47.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 19.9%. Reporting peaked in 2020 at $6,365 and has fallen 64.5% since, to $2,257 in 2025. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,233in general payments, 2019–2025

Across 311 payments — averaging $68.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Liberty Surgical Inc.$4K
  • Stryker$3K
  • Smith+Nephew$2K
  • Orthofix Medical, Inc.$2K
  • Treace Medical Concepts, Inc.$2K
  • Kerecis Limited$1K
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$3001%
  • Travel & lodging$5,79427%
  • Food & beverage$10,13748%
  • Education$4,52121%
  • Other$4802%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,233 in reported general payments places this provider in the 90th percentile of 542 foot & ankle surgery providers in New Jersey.

See all foot & ankle surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$135,060
Medicare patients
240
Services billed
1,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.41$28,914
Ciclopirox105$2,919
Ammonium Lactate170$2,225
Ketoconazole40$873
Diclofenac Sodium32$477
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav43$295
Doxycycline Hyclate21$229
Mupirocin37$227
Ciprofloxacin Hcl22$153
Terbinafine Hcl17$146
Levofloxacin11$98
Meloxicam22$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$2,217$28,91441 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 542 foot & ankle surgery providers in New Jersey.

Other foot & ankle surgery in Millville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →